[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"refractory-t-cellhistiocyte-rich-large-b-cell-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:refractory-t-cellhistiocyte-rich-large-b-cell-lymphoma":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100566025","phase-2-testing-the-effectiveness-of-a-combination-targeted-therapy-vipor-for-patients-with-relapsed-andor-refractory-aggressive-b-cell-lymphoma-100566025",false,"NCT06649812","Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and\u002For Refractory Aggressive B-cell Lymphoma","A Phase II Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)","Inclusion Criteria:\n\n* Patient must be ≥ 18 years of age\n* Patient must have histologically or cytologically confirmed aggressive B-cell lymphoma as follows:\n\n  * Cohort 1: CD10-negative DLBCL, which includes:\n\n    * CD10-negative non-GCB DLBCL, not otherwise specified (NOS) (i.e., CD10-\u002FBCL6- or CD10-\u002FBCL6+\u002FMUM1+ DLBCL)\n    * CD10-negative GCB DLBCL, NOS (i.e., CD10-\u002FBCL6+\u002FMUM1- DLBCL)\n    * CD10-negative HGBCL with MYC and BCL6 (without BCL2) translocations (HGBCL-DH-BCL6)\n    * CD10-negative HGBCL, NOS (without MYC and BCL2 translocations)\n    * CD10-negative T-cell\u002Fhistiocyte-rich large B-cell lymphoma (THRLBCL) OR\n  * Cohort 2: CD10-positive or negative HGBCL with MYC and BCL2 rearrangements (with or without BCL6 rearrangement) (HGBCL-DH-BCL2)\n\n    * NOTE: The site principal investigator must review and verify the pathology report findings to ensure the patient is eligible and is assigned to the respective cohort at the time of registration\n* Patient must have relapsed and\u002For refractory disease after at least 1 prior anthracycline and anti-CD20 antibody-containing regimen\n* Patient must not have confirmed or suspected primary mediastinal large B-cell lymphoma (PMBL)\n* Patient must not be pregnant due to the potential harm to an unborn fetus with the treatment regimens being used.\n\n  * All patients of childbearing potential must have a serum or urine study with a sensitivity of at least 25 mIU\u002FmL within 14 days prior to registration to rule out pregnancy and again within 24 hours prior to starting cycle 1 day 1 of treatment.\n  * A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\n* Patients of childbearing potential must not expect to conceive children by abstaining from sexual intercourse or by using accepted and effective methods of contraception throughout the entire duration of protocol treatment, including during dose interruptions, and for 6 months after the last dose of protocol treatment. Male patients must not father children by abstaining from sexual intercourse or by using a condom during sexual contact with pregnant partners or partners of childbearing potential throughout the entire duration of protocol treatment, including dose interruptions, and for 6 months after the last dose of protocol treatment even if they have had a successful vasectomy\n* Male patients must agree to not donate semen or sperm during the entire duration of protocol treatment or for at least 28 days after the last dose of lenalidomide\n* Patient must agree to abstain from breastfeeding during the entire duration of protocol treatment and for at least 6 months after the last dose of protocol treatment\n* Patient must agree to abstain from donating blood during the entire duration of protocol treatment and for at least 28 days after the last dose of lenalidomide\n* Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and\u002For family member available will also be considered eligible\n* Absolute neutrophil count (ANC) ≥ 1,000\u002FmcL without requirement for granulocyte colony stimulating factor (G-CSF) support (obtained ≤ 7 days prior to registration)\n* Hemoglobin ≥ 8 g\u002FdL (obtained ≤ 7 days prior to registration)\n* Platelets ≥ 75,000\u002FmcL without requirement for platelet transfusion support (obtained ≤ 7 days prior to registration)\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (or ≤ 3.0 x institutional ULN for patients with documented Gilberts syndrome) (obtained ≤ 7 days prior to registration)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 3.0 x institutional ULN (obtained ≤ 7 days prior to registration)\n* Creatinine ≤ 1.5 mg\u002FdL OR creatinine clearance ≥ 30 mL\u002Fmin\u002F1.73 m\\^2 (estimated by Cockcroft-Gault method or measured) (obtained ≤ 7 days prior to registration)\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patient must not have confirmed or suspected primary DLBCL of the central nervous system (CNS) (PCNSL)\n* Patients with history of secondary CNS lymphoma (SCNSL) are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Patient must not have taken or require warfarin or other strong CYP3A inhibitors or inducers within 7 days prior to registration.\n\n  * NOTE: Antiplatelet agents, other anticoagulants aside from warfarin, as well as mild or moderate CYP3A inhibitors or inducers are permitted on study but should be used with caution\n* Patient must not have an uncontrolled intercurrent illness that would interfere with the safety or efficacy assessment of this protocol\n* Patient must not have evidence of an active infection at the time of registration\n* Patient must not have the following current or prior anti-cancer treatment:\n\n  * Any chemotherapy, targeted therapy, anti-cancer antibodies, antibody-drug conjugates, or bi-specific antibodies received within 2 weeks prior to registration\n\n    * NOTE: Short courses of corticosteroids or palliative external beam radiation therapy (XRT) prior to registration are permitted\n  * More than 3 prior lines of cytotoxic chemotherapy, excluding targeted therapy, anti-cancer antibodies, antibody-drug conjugates, bi-specific antibodies, and radio- or toxin-immunoconjugates\n\n    * NOTE: Cytoreductive chemotherapy followed by autologous stem cell transplant (ASCT) counts as 1 line of cytotoxic therapy. Similarly, cytoreductive chemotherapy (either pre-T-cell collection or as bridging therapy) followed by pre-conditioning therapy\u002Fchimeric antigen receptor T-cell (CAR-T) counts as 1 line of therapy, as long as no disease progression occurs between interventions. For both therapies, if progressive disease is documented between 2 distinct regimens, then they should be counted as 2 lines of cytotoxic chemotherapy\n  * Radio- or toxin-immunoconjugates within 10 weeks prior to registration\n  * Previous treatment with more than one of the following study agents: venetoclax (or another BCL2 inhibitor), ibrutinib (or another BTK inhibitor), or lenalidomide (or another immunomodulatory imide drug \\[IMiD\\])\n  * Prior autologous stem cell transplant (ASCT), chimeric antigen receptor T-cell (CAR-T) therapy, or allogeneic stem cell (or other organ) transplant within 3 months prior to registration\n  * Any evidence of active graft-versus-host disease or requirement for immunosuppressants within 28 days prior to registration\n\n    * NOTE: In addition, patient must have recovered (i.e., ≤ grade 1 or baseline) from all adverse events due to previously administered anti-cancer treatment, surgery, or procedure\n    * NOTE: Exceptions to this include events not considered to place the patient at unacceptable risk of participation in the opinion of the treating investigator (i.e., alopecia)\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better\n* Patient must have adequate formalin fixed paraffin embedded (FFPE) tumor tissue specimen from the initial diagnostic biopsy or on-study repeat tumor tissue biopsy for molecular analysis\n\n  * NOTE: Excisional tumor biopsy is preferred. Core needle biopsies will be considered adequate if there is enough tissue for the mandatory molecular analysis. Submission of an entire FFPE tumor block is preferred, but if unavailable 10 x 10um FFPE scrolls may be submitted as an alternative. If adequate archived FFPE tumor tissue is unavailable, the patient must be willing to undergo research biopsy for molecular analysis\n* Patient must have measurable disease\n* Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and\u002For that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and\u002For refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40],"High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified","Recurrent T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified","Refractory T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma","RECRUITING","2026-06-20",{"date":44,"type":45},"2026-06-23","ACTUAL",{"date":47,"type":45},"2025-10-07",{"date":49,"type":20},"2027-09-01",{"name":51,"class":52},"National Cancer Institute (NCI)","NIH",84,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100580213","phase-2-golcadomide-and-rituximab-as-bridging-therapy-for-relapsed-or-refractory-aggressive-b-cell-non-hodgkin-lymphoma-before-car-t-cell-therapy-100580213","NCT06834373","Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","Phase 2 Study of Golcadomide With Rituximab as a Bridging Therapy Prior to CAR-T for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Confirmed pathology diagnosis according to 2016 World Health Organization (WHO) classification including patients with diseases listed below with relapsed, progressive and\u002For refractory disease (Cheson et al. 2014) following treatment with one or two prior lines of standard therapy, no more than two lines of therapy are permitted:\n\n  * Diffuse large B-cell lymphoma not otherwise specified (NOS) including:\n\n    * Transformed lymphoma\n    * Germinal center B-cell type\n    * Activated B-cell type\n  * High-grade B-cell lymphoma (HGBCL), NOS\n  * High grade B-cell lymphoma with MYC and BCL2 translocation\n  * Primary mediastinal (thymic) large B-cell lymphoma\n  * Grade 3B follicular lymphoma\n  * T-cell\u002Fhistiocyte-rich large B-cell lymphoma\n  * Large B-cell lymphoma with IRF4 rearrangement\n  * Primary cutaneous diffuse large B-cell lymphoma (DLBCL), leg type\n  * Epstein-Barr virus (EBV) positive DLBCL, NOS\n  * DLBCL associated with chronic inflammation\n  * Intravascular large B-cell lymphoma\n  * ALK positive large B-cell lymphoma\n  * NOTE: Richters transformation patients are excluded\n* Measurable disease by PET-CT with at least one lymph node or other type of lesion that has a size \\> 1.5 cm in the transverse diameter, as defined by Lugano classification\n\n  * NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible\n* Patient is potentially eligible for CAR-T therapy as determined by treating physician\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\n* Hemoglobin \\> 7.0 g\u002FdL (obtained ≤ 14 days prior to registration)\n* Absolute neutrophil count (ANC) ≥ 1000\u002FmcL (obtained ≤ 14 days prior to registration); growth factor support allowed at physician discretion\n* Platelet count ≥ 75,000\u002FmcL (obtained ≤ 14 days prior to registration)\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration); if total bilirubin is \\> 1.5 ULN, direct bilirubin must be normal\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 x ULN (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma) (obtained ≤ 14 days prior to registration)\n* Calculated creatinine clearance ≥ 45 ml\u002Fmin using the Cockcroft-Gault formula (obtained ≤ 14 days prior to registration)\n* Have 2 negative pregnancy tests as verified by the investigator prior to starting CC-99282:\n\n  * A negative serum pregnancy test (sensitivity of at least 25 mIU\u002FmL) at screening (between 10 to 14 days prior to cycle 1 day 1)\n  * A negative serum or urine pregnancy test (investigator's discretion) within 24 hours prior to cycle 1 day 1 of study treatment\n* Provide written informed consent\n* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n* Subjects must agree not to donate blood while receiving golcadomide, during dose interruptions and for ≥ 28 days following the last dose of golcadomide\n\nExclusion Criteria:\n\n* Any of the following because this study involves an investigational agent that has known genotoxic, mutagenic, and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n* Persons of childbearing potential (and persons able to father a child) who are unwilling to employ adequate contraception\n\n  * Persons of childbearing potential (PCBP) unwilling to use two reliable forms of contraception simultaneously or to practice complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence \\[e.g., calendar, ovulation, symptothermal or postovulation methods\\] and withdrawal are not acceptable methods of contraception) from heterosexual contact during the following time periods related to this study:\n  * For ≥ 28 days before starting treatment, during treatment and dose interruptions, and for ≥ 28 days after the last dose of golcadomide\n  * Examples of highly effective methods of contraception:\n\n    * Intrauterine device (IUD)\n    * Hormonal (birth control pills, injections, implants, levonorgestrel-releasing intrauterine system \\[IUS\\], medroxyprogesterone acetate depot injections, ovulation inhibitory\n    * Progesterone-only pills \\[e.g., desogestrel\\])\n    * Tubal ligation\n    * Partner's vasectomy\n  * Examples of additional effective methods:\n\n    * Male condom\n    * Diaphragm\n    * Cervical cap\n  * Persons who can father a child unwilling to practice complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence \\[e.g., calendar, ovulation, symptothermal or post-ovulation methods\\] and withdrawal are not acceptable methods of contraception.) or unwilling to use a condom during sexual contact with a pregnant person or a PCBP during treatment and dose interruptions, and for \\> 28 days following the last dose of golcadomide, even if they have undergone a successful vasectomy\n  * Persons who can father a child and are unwilling to refrain from donating semen or sperm while receiving golcadomide, during dose interruptions, or for ≥ 28 days following the last dose of golcadomide\n* Life expectancy \\\u003C 3 months\n* Any of the following prior therapies:\n\n  * Any prior CAR-T or other T-cell targeting treatment (approved or investigational) ≤ 4 weeks prior to registration\n  * Any prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to registration, whichever is shorter\n\n    * Exception: Monoclonal and bispecific antibodies is acceptable\n  * Prior therapy with golcadomide ≤ 4 weeks prior to registration\n  * Prior autologous stem cell transplantation (SCT) ≤ 3 months prior to registration. If subject had autologous SCT \\> 3 months prior to the start of registration, any treatment-related toxicity is unresolved (grade \\> 1)\n  * Major surgery ≤ 3 weeks prior to registration\n  * Chemotherapy ≤ 2 weeks prior to registration\n  * Concomitant radiation therapy; local palliative radiotherapy is permitted\n* Co-morbid systemic illnesses or other severe concurrent disease or cancer which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Impaired cardiac function or clinically significant cardiac diseases including, but not limited to:\n\n  * Symptomatic congestive heart failure\n  * History of myocardial infarction ≤ 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n* Uncontrolled intercurrent non-cardiac illness including, but not limited to:\n\n  * Ongoing or active infection\n  * Psychiatric illness\u002Fsocial situations\n  * Dyspnea at rest due to complications of advanced malignancy or other disease that requires continuous oxygen therapy (such as interstitial lung disease or chronic obstructive pulmonary disease \\[COPD\\])\n  * Any other conditions that would limit compliance with study requirements\n* Subject had prior allogeneic SCT with either standard or reduced intensity conditioning ≤ 6 months prior to registration. If subject had prior allogeneic SCT \\> 6 months prior to registration, any treatment-related toxicity is unresolved (grade \\>1)\n* Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy, as there is currently no safety data in HIV positive patients\n* Subject has known chronic active hepatitis B or C virus (HBV\u002FHCV) infection\n\n  * Exception: Patients with HBV and an undetectable viral load who are on suppressive therapy and\u002For those with HCV and an undetectable viral load are allowed\n* Concurrent administration of strong or moderate CYP3A4\u002F5 inhibitors and inducers within 14 days or 5 half-lives, whichever is longer before the study treatment administration\n* Receiving any other investigational agent which would be considered as a treatment for lymphoma.\n\n  * Exception: Corticosteroids are allowed\n* Active second malignancy requiring treatment that would interfere with the assessment of the response of the primary cancer or interpretation of the safety of this protocol therapy\n* History of deep venous thrombosis\u002Fembolism, threatening thromboembolism or known thrombophilia. Patients with a history of deep vein thrombosis (DVT)\u002Fpulmonary embolism (PE) or thrombophilia may still participate if they are willing to be on full anticoagulation during treatment. Full anticoagulation is defined as Warfarin, factor X inhibitors, or low molecular weight heparin at therapeutic doses. The rationale for this requirement is that golcadomide therapy is associated with an increased risk of thrombosis. Patients with no history of DVT\u002FPE or thrombophilia are not required to take anticoagulation and\u002For anti-platelet prophylaxis\n\n  * NOTE: If a patient develops a thrombotic event, they must be able and willing to receive anticoagulation therapy with aspirin 81-325 mg daily prophylaxis, low molecular weight heparin, factor X inhibitors or Warfarin. This is due to an increased risk of thrombosis in patients treated with golcadomide without prophylaxis\n* Live COVID-19 vaccine administered ≤ 28 days prior to registration",{"count":62,"type":20},41,[23],"This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Patients that are able to receive CAR T-cell therapy have a potential for cure, however, many will not be qualified to receive therapy due to relapse. Bridging therapy is therapy intended to transition a patient from one therapy or medication to another or maintain their health or status until they are a candidate for a therapy or have decided on a therapy. Golcadomide may help block the formation, growth or spread of cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving golcadomide and rituximab as bridging therapy before CAR T-cell therapy may kill more tumor cells and may improve the chance of proceeding to CAR T-cell therapy in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.",[66,67,68,69,70,28,29,71,72,73,32,74,75,76,33,77,78,79,80,81,35,36,82,83,84,39,85,86,87,40,88],"Large B-Cell Lymphoma With IRF4 Rearrangement","Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma","Recurrent ALK-Positive Large B-Cell Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation","Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent Grade 3b Follicular Lymphoma","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","Recurrent Intravascular Large B-Cell Lymphoma","Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","Recurrent Primary Mediastinal Large B-Cell Lymphoma","Recurrent Transformed Non-Hodgkin Lymphoma","Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","Refractory ALK-Positive Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation","Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory Grade 3b Follicular Lymphoma","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","Refractory Intravascular Large B-Cell Lymphoma","Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","Refractory Primary Mediastinal Large B-Cell Lymphoma","Refractory Transformed Non-Hodgkin Lymphoma","2026-01-26",{"date":91,"type":45},"2026-01-28",{"date":93,"type":45},"2025-04-02",{"date":95,"type":20},"2027-03-03",{"name":97,"class":98},"Mayo Clinic","OTHER",7]